TLDR: BostonGene, a leader in AI-powered solutions for cancer and the immune system, has been honored with five 2025 Stevie® Awards for Technology Excellence. These accolades recognize the company’s transformative impact on oncology research and development through its advanced multiomic analytics platform and drug repurposing solutions, which leverage artificial intelligence to deliver clinically actionable insights.
WALTHAM, Mass. – October 21, 2025 – BostonGene, a trailblazer in developing the leading AI foundational model for cancer and the immune system, proudly announced today its recognition with five prestigious 2025 Stevie® Awards for Technology Excellence. This significant achievement underscores BostonGene’s pivotal role in advancing oncology drug development and patient care through its innovative AI-powered analytics.
The awards celebrate BostonGene’s multiomic intelligence and AI-driven solutions that empower pharmaceutical companies to de-risk development, accelerate trial timelines, and capture crucial market segments. Andrew Feinberg, President and CEO of BostonGene, expressed his gratitude, stating, “We are honored to receive multiple Stevie Awards recognizing our platform’s transformative impact on oncology R&D. These accolades validate the value we bring to pharma by delivering clinically actionable insights that reduce trial risk, increase regulatory success and ultimately improve patient outcomes.”
BostonGene’s award-winning biomarker discovery platform is built upon AI-driven, multiomic analytics. This sophisticated system integrates various data types, including whole exome sequencing (WES), whole transcriptome sequencing (WTS), circulating tumor DNA (ctDNA), flow cytometry, and spatial proteomics, to provide a comprehensive understanding of cancer.
Furthermore, the company’s drug repurposing solution, also recognized by the awards, offers a data-driven approach to indication expansion. This solution integrates AI-powered molecular profiling with curated clinical literature and extensive drug databases. It meticulously evaluates over 7,000 anti-cancer agents, more than 30,000 publications, and over 10,000 clinical trials to pinpoint unmet clinical needs, competitive gaps, and high-probability, low-risk opportunities for drug repurposing. This innovative approach significantly reduces costs, timelines, and risks, providing a distinct competitive advantage for biopharma innovators.
The Stevie Awards for Technology Excellence, an international business awards competition, recognized BostonGene among other prominent technology leaders such as Amazon, Meta, and IBM, for its five wins. The awards program itself includes ‘Artificial Intelligence’ as one of its key technology-industry sections, highlighting the direct relevance of BostonGene’s work to the AI field.
Also Read:
- The Aspen Group Honored with Brandon Hall Silver Award for Pioneering AI in HR
- Navigating the AI Hype Cycle in Healthcare: Industry Leaders and Media Weigh In on Practicality and Ethics
This recognition follows BostonGene’s earlier achievement in August 2025, when it was named “AI-based Drug Discovery Solution of the Year” in the 8th annual AI Breakthrough Awards program, further solidifying its position as a leader in AI-powered drug discovery and development. BostonGene continues to redefine cancer patient care and drug development by seamlessly integrating omnimodal data with cutting-edge artificial intelligence.
